Martin Volz1, Jens Schaumburger2, Hubert Frick1, Joachim Grifka2, Sven Anders3. 1. Sportklinik Ravensburg, Ravensburg, Germany. 2. Department of Orthopedic Surgery, University of Regensburg, Asklepios Clinical Center Bad Abbach, Bad Abbach, Germany. 3. Department of Orthopedic Surgery, University of Regensburg, Asklepios Clinical Center Bad Abbach, Bad Abbach, Germany. s.anders@asklepios.com.
Abstract
PURPOSE:Autologous Matrix-Induced Chondrogenesis (AMIC®) utilizing a type I/III collagen membrane was compared with microfracture (MFx) alone in focal cartilage lesions of the knee at one, two and five years. METHODS:Forty-seven patients (aged 37 ± 10 years, mean defect size 3.6 ± 1.6 cm2) were randomized and treated either with MFx, with sutured or glued AMIC® in a prospective multicentre clinical trial. RESULTS: After improvement for the first two years in all subgroups, a progressive and significant score degradation was observed in the MFx group, while all functional parameters remained stable for least five years in the AMIC® groups. At two and five years, MRI defect filling was more complete in the AMIC® groups. No treatment-related adverse events were reported. CONCLUSIONS:AMIC® is an effective cartilage repair procedure in the knee resulting in stable clinical results significantly better than the MFx group at five years.
RCT Entities:
PURPOSE: Autologous Matrix-Induced Chondrogenesis (AMIC®) utilizing a type I/III collagen membrane was compared with microfracture (MFx) alone in focal cartilage lesions of the knee at one, two and five years. METHODS: Forty-seven patients (aged 37 ± 10 years, mean defect size 3.6 ± 1.6 cm2) were randomized and treated either with MFx, with sutured or glued AMIC® in a prospective multicentre clinical trial. RESULTS: After improvement for the first two years in all subgroups, a progressive and significant score degradation was observed in the MFx group, while all functional parameters remained stable for least five years in the AMIC® groups. At two and five years, MRI defect filling was more complete in the AMIC® groups. No treatment-related adverse events were reported. CONCLUSIONS: AMIC® is an effective cartilage repair procedure in the knee resulting in stable clinical results significantly better than the MFx group at five years.
Authors: J Richard Steadman; Bruce S Miller; Spero G Karas; Theodore F Schlegel; Karen K Briggs; Richard J Hawkins Journal: J Knee Surg Date: 2003-04 Impact factor: 2.757
Authors: Pierre Mainil-Varlet; Thomas Aigner; Mats Brittberg; Peter Bullough; Anthony Hollander; Ernst Hunziker; Rita Kandel; Stefan Nehrer; Kenneth Pritzker; Sally Roberts; Edouard Stauffer Journal: J Bone Joint Surg Am Date: 2003 Impact factor: 5.284
Authors: P C Kreuz; M R Steinwachs; C Erggelet; S J Krause; G Konrad; M Uhl; N Südkamp Journal: Osteoarthritis Cartilage Date: 2006-07-11 Impact factor: 6.576
Authors: C G Peterfy; A Guermazi; S Zaim; P F J Tirman; Y Miaux; D White; M Kothari; Y Lu; K Fye; S Zhao; H K Genant Journal: Osteoarthritis Cartilage Date: 2004-03 Impact factor: 6.576
Authors: Andrew J Blackman; Matthew V Smith; David C Flanigan; Matthew J Matava; Rick W Wright; Robert H Brophy Journal: Am J Sports Med Date: 2013-04-30 Impact factor: 6.202
Authors: Jonathan S Palmer; A Paul Monk; Sally Hopewell; Lee E Bayliss; William Jackson; David J Beard; Andrew J Price Journal: Cochrane Database Syst Rev Date: 2019-07-19
Authors: Bryan Michael Saltzman; Michael L Redondo; Adam Beer; Eric J Cotter; Rachel M Frank; Adam B Yanke; Brian J Cole Journal: Cartilage Date: 2018-10-31 Impact factor: 4.634
Authors: Alfred Hochrein; Wolfgang Zinser; Gunter Spahn; Peter Angele; Ingo Löer; Dirk Albrecht; Philipp Niemeyer Journal: Int Orthop Date: 2018-08-30 Impact factor: 3.075